Pharmabcine Inc.

Seon Hwan Oh

Sung Woo Kim

Hyuk Jin Lee

Seon Young Lee

Do Yun Kim

Weon Sup Lee

Sang Soon Byun

Jae Bong Yoon

Sang Ryeol Shim

Jin San Yoo

Nam Ye Kim

Jong Geun Jeong

Young Ae Lee

In Sook Park

Sang Hoon Lee

Joong Kyu Kim

Jin Hee Choi

Yeun Ju Kim

Eun Jin Lee

Jin Sang Yoo

Kyung Hee Nahm

Ju Ryung Nam

Bo Young Jeong

Mi Ju Park

Jin Sook Lee

Sung-Woo Kim

Eun Hee Lee

Miju Park

Jinsang Yoo

Youngae Lee

Jinhee Choi

Ji Hye Jeong

Mi Ae Jeon

Yeon Ju Kim

Kyoung Hee Nahm

Boyoung Jeong

Ju Ryoung Nam

Hyuk Joon Lee

The present invention relates to a novel form of a dual-target antibody targeting VEGFR-2 and DLL4, a gene encoding the same, a recombinant expression vector including the gene, host cells transformed with the recombinant expression vector, a method of producing the dual-target antibody using the host cells, a pharmaceutical composition comprising the dual-target antibody.

Dual-target antibody targeting VEGFR-2 and DLL4 and pharmaceutical composition including same

Provided are an antibody specifically bound to c-Met (c-Met-specific antibody) or fragments thereof, and more specifically, a fully human antibody having high affinity and specificity to c-Met isolated from human Fv(ScFv) phage library, a polynucleotide encoding the antibody, a recombinant vector containing the polynucleotide, a cell transformed with the recombinant vector, and a method of producing the c-Met-specific antibody by culturing the cell, wherein the c-Met-specific antibody may effectively control activity of c-Met in vivo.

Human antibody specific to c-Met and preparation method thereof

Dual-target antibody targeting VEGFR-2 and DLL4, and pharmaceutical composition including same

Growing community of inventors

Daejeon, South Korea

Seon Hwan Oh